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➣  The use of illegal drugs remains a serious ThreaT 
to community health.
1 However, despite the substantial 
social costs attributable to illegal drugs, a well-described 
discordance between scientific evidence and policy exists 
in this area,
2 such that most resources go to drug law en-
forcement activities that have not been well evaluated.
3,4 
When the Office of the Auditor General of Canada last 
reviewed the country’s drug strategy, in 2001, it estimat-
ed that of the $454 million spent annually on efforts to 
control illicit drugs, $426 million (93.8%) was devoted to 
law enforcement.
5 The report further concluded, “Of par-
ticular concern is the almost complete absence of basic 
management information on spending of resources, on 
expectations, and on results of an activity that accounts 
for almost $500 million each year.”
5 
Despite the long-standing emphasis on drug law en-
forcement, the federal government has recently fur-
ther prioritized this approach by developing legislation 
requiring mandatory minimum prison sentences for 
minor drug law offences.
6 This article reviews the impact 
of conventional drug policies employed internationally 
and describes evidence-based steps to reduce the health 
and social costs attributable to drug policies in Canada.
Impact of drug law enforcement
Law enforcement has a critical role to play in community 
safety. However, as was observed with the emergence of 
a violent illegal market under alcohol prohibition in the 
United States in the 1920s, the vast illegal market that 
has emerged under drug prohibition has proven remark-
ably resistant to law enforcement efforts, while unintend-
ed consequences have similarly emerged.
4,7 
Given its well-funded drug surveillance systems, the 
United States has generated excellent data for assessing 
the impact of drug law enforcement. Remarkably, de-
spite an estimated US$1 trillion spent since former US 
president Richard Nixon first declared his country’s “war 
on drugs,” the effort to reduce drug supply and drive up 
drug prices through aggressive drug law enforcement 
appears to have been ineffective.
8–10 Instead, in recent 
decades, the prices of the more commonly used illegal 
drugs (e.g., cannabis and cocaine) have actually gone 
down, while potency has risen dramatically.
11,12 To high-
light the limited ability of drug law enforcement to con-
strain cannabis supply, Figure 1 shows that the estimated 
potency of US cannabis (in terms of its active ingredi-
ent, tetrahydrocannabinol) has increased by more than 
170%, from approximately 2.3% in 1981 to 6.3% in 2002, 
despite an increase in US federal anti-drug expenditures 
from US$1.5 billion in 1981 to more than US$18 billion 
in 2002.
8,13
Opponents of drug policy reform commonly argue 
that drug use would increase if health-based models were 
emphasized over drug law enforcement,
14 but we are un-
aware of any research to support this position. In fact, 
a recent World Health Organization study demonstrated 
that international rates of drug use were unrelated to 
how vigorously drug laws were enforced, concluding that 
“countries with stringent user-level illegal drug policies 
did not have lower levels of use than countries with liber-
al ones.”
15 In addition, although reducing the availability 
of cannabis has been a central focus of drug law enforce-
ment efforts, over the past 30 years of cannabis prohibi-
tion the drug has remained “almost universally available 
to American 12th graders,” according to US drug use sur-
veillance systems funded by the US National Institutes 
of Health, with 80%–90% of survey respondents saying 
that the drug is “very easy” or “fairly easy” to obtain.
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United States recently concluded that its US$1.4 billion 
advertising campaign had been ineffective at curtailing 
rates of drug use by youth and may actually have had the 
negative effect of inflating youths’ perceptions regarding 
rates of drug use among their peers.
21
Conversely, a substantial research base points toward 
more effective models that have been proven to reduce 
health-related and community concerns attributable to 
drug use, as well as reducing the unintended effects of 
drug policies.
7,17,22–24 This substantial body of evidence 
leads to several observations, as outlined below.
Evidence-based drug treatment programs are cost 
effective, and significant benefits should be derived, at 
both individual and societal levels, through an increase 
in scale.
25 Consistent with the recent recommendations 
of the House of Commons Standing Committee on Pub-
lic Safety and National Security,
26 this would include 
expanding access to existing evidence-based models of 
care such as medical and non-medical withdrawal pro-
grams, programs to manage concurrent mental health 
problems and addictions, ambulatory and residential 
treatment programs, and opioid substitution therapies.
17 
Similarly, given the substantial health (e.g., infectious 
disease, overdose death) and social (e.g., crime) concerns 
caused by heroin addiction in urban areas
27 and the po-
tential for heroin by prescription to reduce these harms 
among those in whom conventional treatments fail, the 
prescription of heroin could be considered for selected 
patients with opioid addiction that is refractory to all 
other treatment modalities.
23,28,29 
Various harm reduction strategies, such as needle ex-
change programs and methadone maintenance therapy, 
Besides the fact that drug law enforcement is costly 
and ineffective, over-reliance on this approach has also 
resulted in a range of unintended consequences, which 
were recently summarized in the official conference dec-
laration of the XVIII International AIDS Conference in 
Vienna, Austria (Box 1).
17 The International AIDS confer-
ence has become the largest biennial public health con-
ference in the world. The so-called Vienna Declaration 
has now been endorsed by thousands of individuals, in-
cluding leaders in science and medicine, Nobel laureates 
and former heads of state. In Canada, the declaration has 
already been endorsed by the Canadian Public Health 
Association, and by the Urban Public Health Network, 
which represents the medical officers of health of Can-
ada’s 18 largest cities.
Models to reduce harm: those that do not work 
and those that do
Of critical importance to any discussion of efforts to re-
duce harm is the fact that some commonly employed 
school-based drug prevention programs have repeatedly 
been proven ineffective in randomized trials,
18 yet they 
continue to receive substantial federal funding in both the 
United States and Canada.  Other programs, including the 
Canadian federal government’s antidrug media campaign, 
are often implemented without evidence to support their 
efficacy and despite evidence that they may be harmful.
19 
For instance, controlled trials of antidrug media messages 
have suggested that they may result in harmful assump-
tions among youth about drug use.
20 Moreover, a US$42.7 
million federal government–funded evaluation of the on-
going National Youth Anti-Drug Media Campaign in the 
Figure 1 
US funding for drug control and estimated potency of cannabis, 1981–2002. Data from the University  
of Mississippi Cannabis Potency Monitoring Project
13 and the US Office of National Drug Control Policy.
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have also proven effective in reducing drug-related harm 
and have not been associated with unintended conse-
quences.
22 The joint recommendations recently released 
by several United Nations agencies, including the World 
Health  Organization,  provide  a  strong  scientific  basis 
for  expanding  harm  reduction  efforts.
22 Beyond these 
recommendations, the recent consensus statement from 
Canada’s  National  Specialty  Society  for  Community 
Medicine,
30 which endorses the scale-up of supervised 
consumption facilities, reflects the compelling national 
and international evidence to support the controlled 
expansion of these programs in urban areas with high 
concentrations of public drug use and related harms. 
Since 1986, more than 90 supervised drug consumption 
facilities have been set up in Switzerland, the Nether-
lands, Germany, Spain, Luxembourg, Norway, Canada 
and Australia, mainly in cities with large populations of 
street injection drug users.
29,31,32
The criminalization of people who use drugs continues 
to prove ineffective in reducing rates of drug use and has 
instead contributed to substantial health-related harms 
(Box 1).
7 Portugal, which decriminalized all drug use in 
2001, has seen no increases in drug-related harms. In-
stead, a published review of the effects of decriminaliza-
tion noted that this change was followed by “reductions 
in problematic use, drug-related harms and criminal 
justice overcrowding,” with rates of drug use remaining 
among the lowest in the European Union.
24
Accordingly, Canadian society would greatly benefit 
from a reorienting of its drug policies on addiction—
that is, with consideration of addiction as a health issue, 
rather than primarily a criminal justice issue. In this 
context, evidence-based community diversion programs 
for non-violent drug offenders could be expanded and 
evaluated to replace more costly and less effective incar-
ceration efforts.
33,34 In the states of New York, Michigan, 
Massachusetts  and  Connecticut,  for  instance,  manda-
tory minimum legislation for non-violent drug offences 
is being repealed, with several other US jurisdictions set 
to follow suit.
Finally, in light of the simple reality that drug prohibi-
tion has not effectively reduced the availability of most 
illegal drugs and has instead contributed to a vast crim-
inal enterprise and related violence,
4 among other harms, 
alternatives should be prioritized for urgent evaluation.
12 
In addition, controlled regulation of illegal drugs may of-
fer several advantages over the unregulated market cur-
rently controlled by organized crime groups, and there 
is substantial evidence from research on illicit drugs, 
tobacco and alcohol regarding how regulatory tools can 
more safely control drug availability while having the 
potential to positively influence cultural norms related to 
drug use (Table 1).
35–37 For instance, comparisons of can-
nabis use between the United States and Holland, where 
cannabis is sold to adults for recreational use through 
government-sanctioned “coffee shops,” have revealed 
that rates of use are higher in the United States, and re-
searchers have concluded that “Drug policies may have 
less impact on cannabis use than is currently thought.”
38 
Similarly, evaluations of cannabis use by US youth have 
demonstrated that rates of use have not increased in 
states where medical marijuana has been legalized.
39
In  this  context,  several  Canadian  bodies,  includ-
ing the Canadian Public Health Association
40 and the 
Health Officers Council of British Columbia,
41 have re-
cently endorsed the evaluation of a regulated market for 
all currently illegal drugs. Although a full description of 
Box 1
Harms of traditional drug policies, as listed in the Vienna 
Declaration
➣  HIV epidemics fuelled by criminalisation of people who use illicit 
drugs and by prohibitions on the provision of sterile needles and 
opioid substitution treatment.
➣  HIV outbreaks among incarcerated and institutionalised drug users 
as a result of punitive laws and policies and lack of HIV prevention 
services in these settings.
➣  The undermining of public health systems when law enforcement 
drives drug users away from prevention and care services and into 
environments where the risk of infectious disease transmission (e.g., 
HIV, hepatitis C & B, and tuberculosis) and other harms is increased.
➣  A crisis in criminal justice systems as a result of record incarceration 
rates in a number of nations. This has negatively aff  ected the 
social functioning of entire communities. While racial disparities in 
incarceration rates for drug off  ences are evident in countries all over 
the world, the impact has been particularly severe in the US, where 
approximately one in nine African–American males in the age group 
20 to 34 is incarcerated on any given day, primarily as a result of drug 
law enforcement.
➣  Stigma towards people who use illicit drugs, which reinforces the 
political popularity of criminalising drug users and undermines HIV 
prevention and other health promotion eff  orts.
➣  Severe human rights violations, including torture, forced labour, 
inhuman and degrading treatment, and execution of drug off  enders 
in a number of countries.
➣  A massive illicit market worth an estimated annual value of 
US$320 billion. These profi  ts remain entirely outside the control of 
government. They fuel crime, violence and corruption in countless 
urban communities and have destabilized entire countries, such as 
Colombia, Mexico and Afghanistan.
➣  Billions of tax dollars wasted on a “War on Drugs” approach to 
drug control that does not achieve its stated objectives and, instead, 
directly or indirectly contributes to the above harms.
For additional information, see the Vienna Declaration.17Open Medicine 2012;6(1)e38
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regulatory models is outside the scope of this paper, it is 
important to stress that regulatory tools would need to be 
closely evaluated and should be tailored to each specific 
substance. Examples of regulatory tools that have been 
described for cannabis are presented in Table 1.
36 
Advocating for drug policy reform has traditionally 
been politically unpopular, but a recent Angus Reid poll 
estimated that 50% of Canadians already support legal-
ization of cannabis.
42 In this context, it is noteworthy 
that, although cannabis is not free from harms, recent 
reviews have suggested that it is less harmful than many 
currently legal drugs, including alcohol and tobacco, as 
well as several commonly used pharmaceutical drugs.
43 
A recent study based on a 16-level matrix of harm, span-
ning individual physical and social harms, demonstrat-
ed the relative safety of cannabis over alcohol (Figure 
2).
44 In light of the persistently widespread availability 
and relative safety of cannabis in comparison to existing 
legal drugs, as well as the crime and violence that exist 
secondary to prohibition of this drug,
4 there is a need 
for discussion about the optimal regulatory strategy to 
reduce the harms of cannabis use while also reducing 
unintended policy-attributable consequences (e.g., the 
organized crime that has emerged under prohibition).
8,38 
A call for action
In  2005,  as  part  of  the  renewal  of  Canada’s  National 
Drug Strategy, an exhaustive national consultative pro-
cess led by Health Canada and the Canadian Centre on 
Substance Abuse culminated in a “national framework 
for action” to reduce the harms associated with drugs 
in Canada.
45 This inclusive process, which involved all 
stakeholder groups, aimed to remove the rhetoric and 
emotion  that  have  traditionally  guided  Canada’s  re-
sponse to illicit drugs and instead sought to incorporate 
the best available scientific evidence into the country’s 
drug policy. The central aim of the strategy was “to en-
sure that Canadians can live in a society increasingly 
free of the harms associated with problematic substance 
use,” and it differed from the US approach in emphasiz-
ing harm reduction.
45
In 2007, however, the federal government abandoned 
this framework in favour of a new anti-drug strategy, which 
removed support for the evidence-based harm reduction 
programs recommended by the World Health Organiza-
tion. The new strategy has also supported various drug-
use prevention measures that have proven ineffective and 
potentially harmful elsewhere.
18,20,21 Lastly, as described 
above, more recent plans to enact costly mandatory min-
imum sentences for drug law violations highlight a com-
plete departure from evidence-based policy-making.
33
Table 1 
Models and mechanisms for reducing cannabis-related 
harms in a regulated market* 
Model or mechanism Description
Prescription 
or permit system
Prescriptions or permits could be issued 
to individual purchasers, in a manner 
similar to the systems in place at some 
medical cannabis dispensaries.
Licensing system Cannabis dispensaries could be 
issued conditional licences requiring 
compliance with regulatory guidelines.
Purchasing controls Taxation (i.e., increasing consumer price 
barriers) has been shown to affect levels 
of alcohol and tobacco use and could be 
applicable to cannabis.
Sales restrictions Implementing age restrictions similar to 
those in tobacco and alcohol regulations 
could limit access to cannabis among 
youth.
Limiting days and hours of sale of 
alcohol has been shown to affect levels 
of alcohol use and could affect rates of 
cannabis use.
The density of alcohol outlets has been 
associated with rates of alcohol use; 
limiting the density of cannabis outlets 
could similarly limit rates of use.
Restrictions on bulk sales, as employed 
in the Netherlands (where purchases 
are restricted to 5 grams), could help 
to restrict the diversion of cannabis to 
minors.
Restrictions on use Regulatory policies that affect the 
location or circumstances of use and 
allow for limited use in designated 
places, as with the Dutch coffee 
shop model for cannabis, could limit 
uncontrolled and “public nuisance” use.
Strict regulations could prohibit driving 
or operating machinery while impaired.
Marketing Strict regulations on marketing and 
product branding would reduce 
exposure to advertising, which is known 
to aff  ect rates of alcohol and tobacco 
use.
Packaging Tamper-proof packaging, standard 
labelling on content, factual health 
warnings, and no on-pack branding 
or marketing would help to regulate 
cannabis use.
Reducing harm Regulated and controlled availability 
of lesser-strength substances would 
reduce the illegal market for and use 
of higher-potency substances, as has 
occurred with the regulation of alcohol.
Opportunities should be explored to 
change patterns of use toward non-
smoked cannabis.
* For further information, see the report of the Health Offi   cers Council of 
British Columbia.42 Open Medicine 2012;6(1)e39
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Publications in medical journals often attract transi-
ent media attention, but their impact can be short-lived 
without meaningful debate on the part of policy-makers. 
We urge that such an informed debate take place without 
delay to increase the relevance of scientific evidence in 
drug policy decision-making.
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